Spyre Therapeutics (NASDAQ:SYRE) Stock: Insider Scott Burrows Sells 7,500 Shares

October 3, 2026 by InsiderTrades.com

Key Points

CEO Cameron Turtle sold 15,000 Spyre Therapeutics shares at an average price of $92.01, generating $1.38 million. The transaction reduced his ownership by 2.71%, leaving him with 537,540 shares, and was executed under a pre-arranged Rule 10b5-1 plan.
Spyre shares opened at $93.19, with a 12-month range of $15.86 to $110.18 and a market capitalization of approximately $8.19 billion. The company recently exceeded quarterly EPS expectations, reporting a loss of $0.36 versus the consensus estimate of a $0.76 loss.
Analyst sentiment remains generally positive: Spyre has a consensus “Moderate Buy” rating and an average price target of $109.71, while institutional investors own 80.39% of the company.

Spyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report) CFO Scott Burrows sold 7,500 shares of the firm's stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $91.83, for a total transaction of $688,725.00. Following the sale, the chief financial officer owned 79,762 shares of the company's stock, valued at $7,324,544.46. The trade was a 8.59% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Spyre Therapeutics Stock Performance

Spyre Therapeutics stock opened at $93.19 on Friday. The firm has a market cap of $8.19 billion, a price-to-earnings ratio of -47.79 and a beta of 3.10. Spyre Therapeutics, Inc. has a 1 year low of $15.86 and a 1 year high of $110.18. The firm's 50 day moving average price is $95.71 and its two-hundred day moving average price is $81.43.

Spyre Therapeutics (NASDAQ:SYRE - Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.76) by $0.40. As a group, equities analysts predict that Spyre Therapeutics, Inc. will post -2.71 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on SYRE shares. JPMorgan Chase & Co. began coverage on Spyre Therapeutics in a research note on Thursday. They issued an "overweight" rating and a $110.00 price target on the stock. Wells Fargo & Company upped their price objective on shares of Spyre Therapeutics from $90.00 to $115.00 and gave the company an "overweight" rating in a research note on Wednesday, August 5th. Mizuho raised their target price on shares of Spyre Therapeutics from $84.00 to $120.00 and gave the stock an "outperform" rating in a report on Monday, July 13th. Weiss Ratings reissued a "sell (d-)" rating on shares of Spyre Therapeutics in a research report on Tuesday, September 1st. Finally, Wedbush restated an "outperform" rating and set a $123.00 price target on shares of Spyre Therapeutics in a report on Wednesday, September 9th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, Spyre Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $109.71.

Get Our Latest Report on SYRE

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of SYRE. Perceptive Advisors LLC raised its position in Spyre Therapeutics by 23.3% during the first quarter. Perceptive Advisors LLC now owns 3,783,225 shares of the company's stock valued at $190,826,000 after buying an additional 714,000 shares during the period. Capital International Investors boosted its position in Spyre Therapeutics by 46.0% during the 4th quarter. Capital International Investors now owns 3,492,541 shares of the company's stock worth $114,416,000 after acquiring an additional 1,100,000 shares during the period. Commodore Capital LP grew its stake in Spyre Therapeutics by 20.1% during the 4th quarter. Commodore Capital LP now owns 2,388,245 shares of the company's stock valued at $78,239,000 after acquiring an additional 400,161 shares in the last quarter. Bank of America Corp DE grew its stake in Spyre Therapeutics by 192.6% during the 1st quarter. Bank of America Corp DE now owns 1,228,093 shares of the company's stock valued at $61,945,000 after acquiring an additional 808,366 shares in the last quarter. Finally, Candriam S.C.A. grew its stake in Spyre Therapeutics by 43.4% during the 1st quarter. Candriam S.C.A. now owns 610,282 shares of the company's stock valued at $30,783,000 after acquiring an additional 184,748 shares in the last quarter. 80.39% of the stock is owned by institutional investors and hedge funds.

Key Spyre Therapeutics News

Here are the key news stories impacting Spyre Therapeutics this week:

Positive Sentiment: Analyst support strengthened: BTIG Research reaffirmed its “buy” rating and assigned a $121 price target, while JPMorgan initiated coverage with an “overweight” rating and a $110 target. The recommendations imply meaningful potential upside from recent trading levels and provide positive validation for Spyre’s immunology pipeline. BTIG Research rating report
Neutral Sentiment: Employee inducement awards announced: Spyre granted two new employees options covering 21,424 shares and 6,604 restricted stock units. The awards were required to support hiring and are not directly related to clinical or financial results, although they could modestly increase future share dilution. Spyre Therapeutics inducement awards announcement
Negative Sentiment: Multiple insiders sold shares: CEO Cameron Turtle sold 15,000 shares, CFO Scott Burrows sold a combined 25,000 shares, and insider Heidy King-Jones sold 28,933 shares. The transactions represent notable reductions in ownership, particularly King-Jones’s roughly 91% decrease, which may raise caution about insider sentiment. However, all sales were executed under pre-arranged Rule 10b5-1 trading plans, reducing their significance as discretionary signals of declining confidence. Spyre insider trading filing

Spyre Therapeutics Company Profile

(Get Free Report)

Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on developing antibody therapeutics for inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease. The company is working to create next-generation biologic medicines intended to address significant treatment needs in these chronic gastrointestinal conditions.

Spyre's pipeline includes programs directed at validated inflammatory pathways, including interleukin-23 (IL-23) and tumor necrosis factor-like ligand 1A (TL1A).